These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30612138)

  • 21. PRESERVED PROINSULIN SECRETION IN LONG-STANDING TYPE 1 DIABETES.
    Steenkamp DW; Cacicedo JM; Sahin-Efe A; Sullivan C; Sternthal E
    Endocr Pract; 2017 Dec; 23(12):1387-1393. PubMed ID: 29144809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects.
    Jiménez A; Casamitjana R; Flores L; Delgado S; Lacy A; Vidal J
    Ann Surg; 2013 May; 257(5):894-9. PubMed ID: 23579541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of an oral mixed meal plus arginine and intravenous glucose, GLP-1 plus arginine to unmask residual islet function in longstanding type 1 diabetes.
    Uitbeijerse BS; Nijhoff MF; de Koning EJP
    Am J Physiol Endocrinol Metab; 2024 May; 326(5):E673-E680. PubMed ID: 38446636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes.
    Kaas A; Andersen ML; Fredheim S; Hougaard P; Buschard K; Petersen JS; de Beaufort C; Robertson KJ; Hansen L; Mortensen HB; Nielsen LB;
    Pediatr Diabetes; 2012 Feb; 13(1):51-8. PubMed ID: 22118630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
    Deng Y; Zhang Y; Zheng S; Hong J; Wang C; Liu T; Sun Z; Gu W; Gu Y; Shi J; Yao S; Wang W; Ning G
    J Diabetes; 2015 Nov; 7(6):820-9. PubMed ID: 25395350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy.
    Barbot M; Mondin A; Regazzo D; Guarnotta V; Basso D; Giordano C; Scaroni C; Ceccato F
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of residual β cell function in long-standing type 1 diabetes.
    Sherr JL; Ghazi T; Wurtz A; Rink L; Herold KC
    Diabetes Metab Res Rev; 2014 Feb; 30(2):154-62. PubMed ID: 24115337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes.
    Asmar M; Højberg PV; Deacon CF; Hare K; Holst JJ; Madsbad S
    Regul Pept; 2010 Feb; 160(1-3):175-80. PubMed ID: 20005261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
    Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
    Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
    Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
    Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
    Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incretins and Their Endocrine and Metabolic Functions.
    Seufert J
    Endocr Dev; 2017; 32():38-48. PubMed ID: 28873383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.